Immuno-Oncology Summit Distinguished Speakers

View Speaker Biographies 


  • Daniel Abate-Daga, PhD, Assistant Member, Immunology Program, H. Lee Moffitt Cancer Center
  • Michael Aberman, MD, President, CEO, Quentis Therapeutics, Inc.
  • Andrew Allen, MD, PhD, President and CEO, Gritstone Oncology
  • Rodabe Amaria, MD, Assistant Professor, Melanoma Medical Oncology, MD Anderson Cancer Center
  • David E. Anderson, PhD, CSO, VBI Vaccines
  • Thomas Lars Andresen, PhD, CSO and Co-Founder, Torque Therapeutics
  • Philip Arlen, MD, President & CEO, Precision Biologics
  • Tara Arvedson, PhD, Director, Oncology Research, Amgen
  • Jessica Baker-Flechtner, PhD, CSO, Genocea Biosciences
  • Roger R. Beerli, PhD, CSO, NBE-Therapeutics AG
  • John Bell, PhD, Senior Scientist, Center for Innovative Cancer Research, Ottawa Hospital Research Institute
  • Jay A. Berzofsky, MD, PhD, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute
  • Marijo Bilusic, MD, PhD, Associate Research Physician, Program Director, NIH Hematology Oncology Fellowship, National Cancer Institute, National Institutes of Health
  • Jeroen H. Blokhuis, PhD, Director, Business Development, Partnerships, Parker Institute for Cancer Immunotherapy
  • Genevieve Boland, MD, PhD, Assistant Professor, Surgery; Director, Melanoma Surgery Program, Massachusetts General Hospital
  • Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company
  • Tullia Bruno, PhD, Assistant Professor, Immunology, University of Pittsburgh Hillman Cancer Center
  • John Burke, PhD, Co-Founder, President and CEO, Applied BioMath, LLC
  • Pamela Carroll, PhD, Senior Vice President, Immuno-Oncology, Genocea Biosciences
  • Manel Cascallo, PhD., CEO, VCN Bioscience
  • Preet M. Chaudhary, MD, PhD, Professor and Chief of Hematology and Director of Blood and Marrow Transplant, Jane Anne Nohl Division of Hematology, University of Southern California Keck School of Medicine
  • Brian Champion, PhD, CSO, Psioxus Therapeutics
  • Huabiao Chen, MD, PhD, Principal Investigator, Vaccine & Immunotherapy Center; Instructor, Medicine, Harvard Medical School
  • Virna Cortez-Retamozo, PhD, Lab Head, Senior Scientist, Oncology-Pharmacology, Sanofi
  • Ildiko Csiki, MD, PhD, Chief Medical Officer, Sensei Biotherapeutics
  • Michael A. Curran, PhD, Associate Professor, Immunology, Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center
  • Stephen Curtis, PhD, Managing Director, MPM Capital
  • John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor
  • Scott M. DeWire, PhD, Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Robert O. Dillman, MD, CMO, AIVITA Biomedical
  • Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen
  • Sean Downing, PhD, MBA, Director, Customer Engagement, Ultivue
  • Boro Dropulic, PhD, CSO, General Manager, Lentigen Technology, Inc., a Miltenyi Biotec company
  • Bob DuBridge, PhD, EVP, Research & CTO, Maverick Therapeutics
  • Carolyn Edwards, PhD, Principal Scientist, Crescendo Biologics
  • Jessie English, PhD, CSO, Tilos Therapeutics
  • Shawn Fahl, PhD, Senior Research Scientist, Discovery Life Sciences
  • Denise Faustman, MD, PhD, Associate Professor & Director, Immunobiology Lab, Massachusetts General Hospital, Harvard Medical School
  • Soldano Ferrone, MD, PhD, Professor in Residence, Surgical Oncology, Massachusetts General Hospital, Harvard Medical School
  • Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumor Immunology, Providence Health & Services; CEO, UbiVac
  • Agnete Fredriksen, PhD, CSO, Vaccibody
  • Sofia Gameiro, PharmD, PhD, Head, Immunomodulation Group, Laboratory of Tumor Immunology and Biology, NCI, NIH
  • Christian Gieffers, PhD, Vice President, Early Drug Development, Apogenix AG
  • Joseph C. Glorioso, PhD, Professor, Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine
  • Stefan Glueck, MD, PhD, FRCPC, Professor of Medicine, Vice President, GMA Early Assets, Celgene Corporation
  • Joel Goldstein, PhD, Senior Director, R&D, Celldex Therapeutics
  • Paola Grandi, PhD, CSO, Cold Genesys
  • John Gustofson, Managing Director, AbbVie Ventures
  • Samir Hanash MD, PhD, Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center
  • Brent Hanks, MD, PhD, Assistant Professor, Medicine, Assistant Professor, Pharmacology and Cancer Biology, Duke Cancer Institute, Duke University School of Medicine
  • Christopher J. Harvey, PhD, Director of Preclinical Sciences and JTX-2011 Scientific Lead, Jounce Therapeutics
  • William Hastings, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research
  • Cara Haymaker, PhD, Assistant Professor, Director, Oncology Research and Immuno-Monitoring Core (ORION), Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
  • Christopher Helsen, PhD, Director, R&D, Triumvira
  • Fred R. Hirsch, MD, PhD, Professor, Medicine, Icahn School of Medicine at Mount Sinai; Executive Director, Clinical Institute for Lung Cancer, Mount Sinai Health Care
  • Eric Holland, MD, PhD, Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center
  • Caron Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana Farber Cancer Institute
  • Russell W. Jenkins, MD, PhD, Assistant Professor, Dept. of Medicine, Center for Cancer Research, Massachusetts General Hospital
  • Thomas Jensen, CEO, Intomics
  • Alexis Ji, PhD, Partner, Illumina Ventures
  • Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research
  • Maria Jure-Kunkel, PhD, Head, Late Stage Oncology Translational Medicine, Genmab
  • Maria Karasarides, PhD, Executive Director, Immuno-Oncology Global Development, Regeneron Pharmaceuticals
  • Noriyuki Kasahara, MD, PhD, Alvera L. Kan Endowed Chair, Professor in Residence, Departments of Neurological Surgery and Radiation Oncology, University of California
  • Yisrael Katz, MD, CMO, Calviri; Center for Innovations in Medicine, Arizona Biodesign Institute
  • Howard Kaufman, PhD, CMO, Replimmune
  • Balveen Kaur PhD, Professor, Vice-Chair Research, John P. and Kathrine G. McGovern Endowed Chair, Smith Department of Neurosurgery, University of Texas
  • Christopher Kemball, PhD, Scientist, Biochemical & Cellular Pharmacology, Genentech
  • John M. Kirkwood, MD, Usher Professor of Medicine, Dermatology and Translational Science, Co-Leader, Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center
  • David Kirn, MD, Co-Founder & Executive Chairman, IGNITE Immunotherapy
  • Emilee Knowlton, PhD, Immunology Sales Specialist, Sales, ProImmune Inc.
  • Keith Knutson, PhD, Professor, Immunology; Director, Immunology & Immunotherapy Program, Mayo Clinic
  • Tania Konry, PhD, Assistant Professor, Pharmaceutical Sciences, Northeastern University
  • Arthur Krieg, MD, Founder & CSO, Checkmate Pharmaceuticals
  • Joseph Krueger, PhD, Vice President, Research and Applications for Advanced Pathology Services, Invicro, LLC
  • Doron Levy, PhD, Professor, Department of Mathematics, University of Maryland
  • Jing Li, Senior Vice President, Discovery, WuXi Biologics
  • Qingcong Lin, PhD, CEO, Biocytogen Boston Corp.
  • Charlene Liao, PhD, President and CEO, Immune-Onc Therapeutics
  • Wei Lin, PhD, Senior Vice President, Oncology Development, Nektar Therapeutics
  • Bolan Linghu, PhD, Principal Scientist, Oncology Bioinformatics, AstraZeneca
  • Junjian Liu, PhD, Vice President, Head of Drug Discovery and Preclinical Development, Innovent Biologics
  • Paul Macklin, PhD, Associate Professor, Intelligent Systems Engineering, Indiana University
  • Ravi Madan, MD, Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute
  • Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute
  • Junko Matsuzaki, PhD, Assistant Professor, Oncology; Director, Immune Analysis Shared Resource, Roswell Park Comprehensive Cancer Center
  • Kathryn McCabe, PhD, Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company
  • Sean McClain, CEO, AbSci
  • Paula Miliani de Marval, Research Associate Director, Charles River
  • Lance D. Miller, PhD, Associate Professor, Cancer Biology; Director, Breast Cancer Center of Excellence; Co-Director, Cancer Genomics Shared Resource, Wake Forest Baptist Comprehensive Cancer Center
  • Michael C. Milone, MD, PhD, Associate Professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
  • Patrice M. Milos, PhD, Co-Founder/President and CEO, Medley Genomics Inc.
  • Greg Motz, PhD, Director, Immunopharmacology, Unum Therapeutics
  • Philipp Müller, PhD, Principal Scientist, Cancer Immunology, Boehringer Ingelheim
  • Matthew Mulvey, PhD, CEO, BeneVir Biopharm, Inc.
  • Viswanathan Muthusamy, PhD, Director, Center for Precision Cancer Modeling, Yale University
  • Cokey Nguyen, PhD, Senior Director, Oncology R&D, Pfizer
  • Olivier Nolan-Stevaux, PhD, Principal Scientist, Oncology-Immunology Research, Amgen
  • Kerri-Ann Norton, PhD, Assistant Professor, Computer Science Program, Department of Science, Mathematics, and Computing, Bard College
  • Kelly Oliner, PhD, Senior Director, Translational Medicine, Diagnostics and Regulatory, WuXi NextCODE
  • Willem Overwijk, PhD, Vice President, Oncology Research, Nektar Therapeutics
  • Mark Paris, PhD, Director, Translational Applications, Biopharma Business Development, Mitra Biotech, Inc.
  • Marcelo Pasquini, MD, MS, Senior Scientific Director, CIBMTR Clinical Trials Support; Associate Professor of Medicine, Medical College of Wisconsin
  • Sari Pesonen, PhD, VP, Scientific and Clinical Development, Valo Therapeutics
  • Laurent Poirot, PhD, Head, Early Discovery, Cellectis
  • Michael Ports, PhD, Associate Director, IO & Cellular Therapy Research, Juno Therapeutics
  • Iulian Pruteanu-Malinici, PhD, Investigator III, Lab Head, Immuno-Oncology, Novartis
  • John Quackenbush, PhD, Henry Pickering Walcott Professor of Computational Biology and Bioinformatics; Chair, Department of Biostatistics, Harvard T.H. Chan School of Public Health
  • Christophe Queva, PhD, CSO, Oncorus
  • Samuel D. Rabkin, PhD, Professor, Neurosurgery, Massachusetts General Hospital and Harvard Medical School
  • Lotta Räty, Product Manager, Cell Separation Automation, Marketing, Miltenyi Biotec GmbH
  • Andreas Raue, Director, Immuno-Oncology, Merrimack Pharmaceuticals, Inc.
  • David A. Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Professor, Medicine, Harvard Medical School
  • Carsten Reinhardt, MD, PhD, Managing Director, CMO, Immatics Biotechnologies
  • Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center
  • John Rossi, Director, Translational Medicine, Kite Pharma
  • Marco Ruella, MD, Assistant Professor of Medicine and Scientific Director, Lymphoma Program, Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania
  • Stephen J. Russell, MD, PhD, CEO, Vyriad, Inc.
  • Eske Rygaard-Hjalsted, MSc, Vice President, Sales, Marketing and BD, Intomics
  • Catherine Sabatos-Peyton, PhD, Director, Exploratory Immuno-Oncology, Novartis
  • Sam Saibil, MD, PhD, Translational Research Fellow, Tumour Immunotherapy Program, Princess Margaret Cancer Centre
  • Shahram Salek-Ardakani, PhD, Director, Cancer Immunology, Pfizer
  • Niranjan Y. Sardesai, PhD, Co-Founder, CEO & President, Geneos Therapeutics
  • Elisa Scarselli, Chief Scientific Officer, Nouscom AG
  • Stephen P. Schoenberger, PhD, Co-Director, San Diego Center for Precision Immunotherapy; Professor, La Jolla Institute for Allergy and Immunology
  • Donald R. Shaffer, PhD, Director, Head of Discovery, Jounce Therapeutics
  • Setareh Shamsili, MD, PhD, Global Consultant Oncology Drug Development          
  • Fiona Sharp, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research
  • John-William Sidhom, MSE, MD/PhD Candidate, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Department of Biomedical Engineering, Johns Hopkins University School of Medicine
  • Alexandre Simonin, PhD, Director, mAb Discovery, Numab Innovation AG
  • Will Singleterry, PhD, Director, Collaborations, Cancer Immunology Team, IsoPlexis
  • Dimitris Skokos, PhD, Director, Immune & Inflammatory Diseases, Regeneron Pharmaceuticals
  • Eric Smith, PhD, Director, Bispecific Antibodies, Regeneron Pharmaceuticals
  • Eric Smith, MD, PhD, Director of Translational Development, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center
  • Qinghua Song, PhD, Director, Biostatistics, Kite, a Gilead Company
  • Stefani Spranger, PhD, Assistant Professor, Biology, Koch Institute for Integrative Cancer Research, MIT
  • Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center & Professor of Immunology and Medicine, University of Connecticut School of Medicine
  • Masataka Suzuki, PhD, Assistant Professor, Center for Cell & Gene Therapy, Dept. of Medicine, Baylor College of Medicine
  • Raymond Tesi, MD, CEO/CMO, INmune Bio
  • Christopher Thanos, PhD, CEO, Cofounder, Actym Therapeutics, Inc.
  • Mark Throsby, PhD, Executive Vice President & CSO, Merus NV
  • Bob Uger, PhD, CSO, Trillium Therapeutics, Inc.
  • Wim van Schooten, PhD, CSO, TeneoBio
  • Scott Tomlins, MD, PhD, CMO, Strata Oncology
  • Lalitha Vijayakrishnan, PhD, Associate Research Director, Discovery Biology, Syngene International Ltd.
  • Alexandra-Chloé Villani, PhD, Associate Scientist, Broad Institute of MIT and Harvard
  • Nathaniel Wang, PhD, Head of R&D, Synthetic Genomics, Inc.
  • Andrew Weinberg, PhD, Chief, Laboratory of Basic Immunology, Providence Health & Services
  • Danny Wells, PhD, Lead Bioinformatics Scientist, Parker Institute for Cancer Immunotherapy
  • Theresa Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, Hillman Cancer Center, University of Pittsburgh School of Medicine
  • Chan Whiting, PhD, Senior Vice President, R&D, Tempest Therapeutics
  • Michael Wichroski, PhD, Senior Principal Scientist, Immuno-Oncology, Bristol-Myers Squibb
  • Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics
  • K. Dane Wittrup, PhD, Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
  • Michael Woo, MBA, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.
  • David Wustrow, PhD, Senior Vice President, Discovery and Preclinical Development, RAPT Therapeutics
  • Yiyi Yan, MD, PhD, Assistant Professor, Medicine and Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN
  • Yong-Guang Yang, MD, PhD, Professor, Columbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons
  • Sawsan Youssef, PhD, Director, Immunology & Immuno Oncology, Distributed Bio
  • Xin Yu, PhD, Scientist, Immuno-Oncology, Amgen
  • Simge G. Yüz, Scientist, NMI Natural and Medical Sciences Institute at the University of Tübingen
  • Litao Zhang, PhD, Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb

Connect With Us


For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute


For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286


For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415